Lantheus-Curium Merger Faces Extended FTC Review as HSR Filing Withdrawn and Refiled
LNTH has more than doubled off its 52-week low of $49.67.
Summary
Lantheus disclosed that Curium withdrew and refiled its HSR antitrust notification, extending FTC review and pushing expected merger closing to the first half of 2027.
Key Events · M&A and Partnerships · LNTH
-
HSR Filing Withdrawn and Refiled
Parent voluntarily withdrew its HSR pre-merger notification on September 17, 2026, and resubmitted on September 21, 2026, to give the FTC additional review time.
-
New Antitrust Waiting Period
The refiling starts a new 30-day HSR waiting period expiring October 21, 2026, unless terminated earlier or extended by an FTC second request.
-
Merger Timeline Extended
The parties now expect to consummate the merger in the first half of 2027, subject to regulatory approvals, stockholder adoption, and other closing conditions.
-
Stockholder Vote Unchanged
The October 14, 2026 special meeting to vote on the $8 billion Curium acquisition remains scheduled as previously disclosed in the September 8 definitive proxy.
Analysis · LNTH · Life Sciences
The $8 billion Curium acquisition just hit a regulatory speed bump. Parent withdrew its HSR filing on September 17 and refiled on September 21, restarting the 30-day antitrust clock. The new waiting period runs to October 21, 2026, and the parties now expect to close in the first half of 2027 — a shift from the previously implied timeline. Withdraw-and-refile is a routine FTC procedure, but it signals the FTC wants more time to scrutinize the deal, which could mean a second request for information and further delay. The October 14 stockholder vote remains on track, but the regulatory path is now longer and less certain.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1531 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LNTH was trading at $100.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $49.67 to $111.86. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.